PHI-101

DB17237InvestigationalSmall molecule

PHI-101: Overview.

Mechanism: Pharmacologically active on Receptor-type tyrosine-protein kinase FLT3 and Serine/threonine-protein kinase Chk2
Curator reviewed
Formula / weight: C₁₉H₁₉FN₄O₂S · 386.45 g/mol (avg)
Also known as: 2-thiophenecarboxamide, 3-((aminocarbonyl)amino)-5-(2-(3-fluorophenyl)ethynyl)-n-(3s)-3-piperidinyl- · N-(2-(n-((3s)(3-piperidyl))carbamoyl)-5-(2-(3-fluorophenyl)ethynyl)(3-thienyl))aminamide
Code names: PHI-101

Resolves to

Compound

Structure

InChIKeyULVAGWVTXBTFRN-AWEZNQCLSA-NSMILESNC(=O)NC1=C(SC(=C1)C#CC1=CC=CC(F)=C1)C(=O)N[C@H]1CCCNC1

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with PHI-101, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.